Aims Population surveys of Type 2 diabetes mellitus and obesity conducted in Samoa over three decades have used varying methodologies and definitions. This study standardizes measures, and trends of Type 2 diabetes mellitus and obesity for 1978-2013 are projected to 2020 for adults aged 25-64 years.
Introduction
The Global Burden of Disease (GBD) Study 2010 estimated that global age-standardized diabetes mortality increased from 16.3 to 19.5/100 000 over 1990-2010 [1] . Although this includes all forms of diabetes, it can be inferred that mortality rates for Type 2 diabetes mellitus have increased because~5-10% of all diabetes cases are Type 1 [2] . Obesity, assessed as BMI ≥ 30 kg/m 2 [3] , is the most significant risk factor for Type 2 diabetes mellitus [3] . Over the past three decades, non-communicable disease (NCD) surveys have been conducted in Samoa, each with somewhat different methods and definitions of Type 2 diabetes mellitus and obesity, which has prevented accurate estimations of period trends [4] . In the 2002 World Health Organization (WHO) STEPS survey, Type 2 diabetes mellitus prevalence was estimated as 21.5% and obesity prevalence 54.8% [5] . Type 2 diabetes mellitus prevalence from the 2013 STEPS survey was reported to be 45.8% [6] .
This study calculates comparable population-based Type 2 diabetes mellitus and obesity measures from empirical surveys to produce prevalence period trends , and projects Type 2 diabetes mellitus and obesity prevalence in Samoa to 2020.
Methods

Study design
Survey inclusion criteria were: (a) contain blood glucose and Type 2 diabetes mellitus information, and anthropometric measurements; (b) can be disaggregated by age, sex and Division of residence; and (c) designed to be nationally representative, or could be adjusted to reflect national demographic characteristics. Eight studies were included: the 1978 Non-Communicable Disease Risk Factor (NCDRF) survey (n = 1079) [7] , repeated in 1991 (n = 1532) [8, 9] ; the Samoan Adiposity and Cardiovascular Disease Risk Factor (SACRF) longitudinal study in 1991 (n = 748) and 1995 (n = 719) [10] ; the 2002 Samoa STEPS (n = 2554) [5] ; the 2003 Samoan Family Study of Overweight and Diabetes (SFSOD) (n = 684) [11] ; the 2010 Genome-Wide Association Study (GWAS, n = 3468) [12] ; and the Samoa 2013 STEPS (n = 1725) [6] .
Excluded are two single-village studies: the 1979 (n = 336) and 1982 (n = 661) surveys from the Samoan Studies Project [13] and a 2009 obesity prevalence survey [14] (n = 85, aged ≥ 40 years).
Population and samples
On the main island of Upolu (76% of the population), the administrative Divisions are: Apia (capital), officially the only urban area; North West Upolu, adjacent to Apia and with the international airport and inter-island ferry terminal, it can be considered peri-urban or semi-rural; the rural areas of Rest of Upolu, and the smaller island of Savai'i although Tuasivi, with the ferry terminal and government centre, could be considered semi-rural [15] .
The Samoan population structure is largely unchanged over the past 30 years due to high out-migration counterbalanced by high total fertility rates of 4.7/woman over 1981-2011 [15, 16] . Population growth was relatively stable at 0.1% (1981) (1982) (1983) (1984) (1985) and 0.8% (2006) (2007) (2008) (2009) (2010) (2011) [16] . Over the period 1981-2011, adults aged 55-64 years (proportion of 25-64 years) made up 14-15% of the population, and the urban proportion was between 21% and 20% of the total [15, 16] . The male-to-female ratio remained almost unchanged over three decades at 1.08 in 1981 and 1.07 in 2011 [15, 16] . Only non-pregnant participants aged 25-64 years were included in the analyses. Surveys were adjusted by Division and age for each sex to the nearest previous census to reduce selection bias, increase national representativeness and minimize heterogeneity between surveys. Response rates for randomly selected eligible participants were: 76% (1978 NCVDS) [7] , 73% (1991 NCVDS) [8, 9] , > 90% (1991 and 1995 SACRF) [10] , 97% (2002 STEPS) [5] , 64% (2013 STEPS, due to cyclone after-effects) [6] , and 85% (2010 GWAS) [12] ; the 2003 SFSOD response rates were not reported [11] .
Except for the 1991 and 1995 SACRF surveys, case weights by Division and 10-year age groups for each sex were calculated by dividing the subgroup proportion in the nearest previous census by the proportion of the same subgroup in each survey. Case weights were applied and Type 2 diabetes mellitus and obesity prevalence, and mean fasting plasma glucose and BMI (and their standard errors, SE) were then calculated from each survey. For the 1991 and 1995 SACRF surveys, sex-specific prevalences and means (and SE) were derived as aggregate data, because of the need to adjust Type 2 diabetes mellitus case enumeration (Appendix S1), and then directly standardized for each sex by age and Division to the nearest previous census.
The 1978 and 1991 NCDRF surveys were designed to examine NCD risk factor differences between indicative samples of urban and rural areas. These surveys had equal numbers of urban and rural participants, but did not sample in the North West Division. Tuasivi in Savai'i was included, which is likely less rural than the rest of Savai'i. Thus, participants from Savai'i in the NCDRF surveys could be considered as semi-rural, and somewhat similar in economic circumstances to North West Upolu.
Participant selection in the 2003 SFSOD was conducted informally and non-randomly (Appendix S2). The 2010 GWAS aimed to recruit a nationally representative sample, but was over-represented by the Rest of Upolu and Savai'i Divisions, and older age groups. These surveys were adjusted accordingly using case weights described above.
The 2002 STEPS survey did not include participants from North West Upolu. Case weights were applied to reduce selection bias. Participants in the 2013 STEPS survey were selected to be nationally representative based on the 2011 census, but case weights were applied to minimize residual selection bias from differential response.
Measurement, data collection and adjustments
Individual record data were available from all surveys, and were used to calculate prevalences and adjust for measurement and selection biases. The 2002 and 2011 STEPS surveys measured glucose from capillary (whole) blood specimens using a point-of-care device. All other surveys collected venous blood samples, which were centrifuged and frozen before transportation to Australia • This is the first study to standardize previously conducted, disparate population-based measures of Type 2 diabetes mellitus and obesity from unit records of empirical surveys to produce period trends in Samoa.
• Prevalences of Type 2 diabetes mellitus and obesity have increased over 35 years , and are projected to continue to increase in the near future.
• The increase in Type 2 diabetes mellitus is partially attributed to the rise in obesity and effective interventions to reduce obesity are urgently required. survey, glucose measurements were standardized to one diagnostic criterion to reduce measurement bias.
Diabetes
The current WHO Type 2 diabetes mellitus definition is a fasting plasma glucose ≥ 7.0 mmol/l and/or on medication for Type 2 diabetes mellitus [17] . In all surveys, only those positively identified as fasting were included in analyses. For further details on Type 2 diabetes mellitus designation see Appendix S3. The WHO definition [17] was applied to the 1978 and 1991 NCDRF. The 2003 SFSOD and 2010 GWAS surveys used fasting venous serum instead of plasma. These values were converted to plasma-equivalent using: -0.137 + 1.047x, where x is serum glucose (mmol/l) [18] . Type 2 diabetes mellitus for the 2003 and 2010 surveys was defined as (converted) fasting plasma glucose ≥ 7.0 mmol/l and/or on medication. For the 1991 and 1995 SACRF, which excluded known Type 2 diabetes mellitus or hypertension, a corrected Type 2 diabetes mellitus prevalence (after conversion from serum to plasma glucose) for each sex and age group was estimated by applying a ratio of known-to-new Type 2 diabetes mellitus cases (Appendix S1). The 2002 STEPS surveys measured capillary (whole) blood with a Roche Accutrend â GCT glucose meter which tested whole-blood specimens and produced whole-blood glucose concentrations, requiring a cut-point for Type 2 diabetes mellitus as fasting whole blood ≥ 6.1 mmol/l (and/or on medication), instead of using fasting plasma glucose ≥ 7.0 mmol/l, which is appropriate for glucose meters that produce glucose in plasma concentrations [17] . For mean fasting plasma glucose analyses, individual glucose readings in the 2002 STEPS survey were multiplied by 1.11 for conversion to a plasma-equivalent measure to calculate mean values, in accordance with recommendations from the International Federation of Clinical Chemistry (IFCC) in 2006 [19] . For 2013 STEPS, Type 2 diabetes mellitus was derived from unit record data using a cutoff point of ≥ 7.0 mmol/l (and/or on Type 2 diabetes mellitus medication) because the Roche Accutrend â plus glucose meter was manufactured after the IFCC recommendations of 2006 for point-of-care devices using whole blood to calibrate results to plasma equivalents [19] ; the upper limit given in Roche Accutrend â plus documentation for impaired fasting glucose of 6.9 mmol/l [20] corresponds to the WHO definition based on fasting plasma glucose [17] (Appendix S3).
Obesity
BMI was calculated as weight/height 2 (kg/m 2 ). In this study, obesity prevalence was defined using the WHO (standard) guideline [3] ≥ 30 kg/m 2 , and the suggested ethnic-specific cut-off points (BMI > 32 kg/m 2 ) [21] because Polynesians have higher muscle-to-fat ratios than Europids. The 1991 and 1995 SACRF were adjusted to correct for obesity under-enumeration from exclusion of known Type 2 diabetes mellitus and known hypertension (on medication).
The numerator and denominator were adjusted using ratios of known: new Type 2 diabetes mellitus and/or hypertensive cases in obese populations derived from the 1991 NCDRF survey (Appendix S4).
Trend analysis
Period trends in prevalence (following logit transformation) were analysed using random effects meta-regression for each sex, and prevalence of Type 2 diabetes mellitus and obesity with 95% prediction intervals (PI) were projected for 2014-2020. Period trends for mean fasting plasma glucose and mean BMI were analysed using linear meta-regression.
A sensitivity analysis of Type 2 diabetes mellitus and obesity trends from meta-regression was for all eight surveys compared with six surveys that excluded the 1991 and 1995 SACRF surveys -from which prevalence was adjusted to incorporate estimates of known Type 2 diabetes mellitus and hypertensive cases that were omitted at the participant selection stage.
Effects of changes of BMI on period trends of Type 2 diabetes mellitus
Because population subgroup Type 2 diabetes mellitus and obesity were adjusted using ratios in the 1991 and 1995 SACRF yielding count data, strata analysis (using Poisson regression) of the combined surveys was undertaken. The strata consisted of: survey (8), Division (4), sex (2) and age groups (4), totalling 256 strata (n = 12 516). Each stratum contained Type 2 diabetes mellitus and population counts, mean BMI, and were weighted by Division and age for each period and sex to the nearest previous census. Poisson regression, using log of the stratum population as an offset, was used to analyse the effects of increasing BMI on Type 2 diabetes mellitus prevalence increase over 1978-2013. Type 2 diabetes mellitus counts were modelled with period (model 1), period and age (model 2), and period, age and BMI (model 3). The relative risk (RR) for Type 2 diabetes mellitus in 2013 was compared with 1978 (referent) for each model. The difference in RR between models 1 and 2 indicated the contribution of age to Type 2 diabetes mellitus and obesity trends over 30 years. The difference in RR between models 2 and 3 indicated the contribution of BMI to Type 2 diabetes mellitus trend over 30 years, adjusting for age.
Results
Diabetes
From meta-regression estimates, Type 2 diabetes mellitus prevalence increased from 1.2% in 1978 to 19.6% in 2013 in men (2.9% per 5 years, P < 0.0001), and from 2.2% to 19.5% in women (2.2% per 5 years, P < 0.0001) ( Table 1 , Fig. 1 ). Empirical estimates from surveys are presented in Table 2 . Type 2 diabetes mellitus prevalence increased in all . Sex-specific estimates adjusted for Division of residence and age to most recent previous census. National estimates adjusted for Division of residence, sex and age. Test for trend from random effects meta-regression after logit transformation of prevalences, or linear trends (means). All trends are statistically significant at P < 0.05, except mean fasting plasma glucose in men (P = 0.07). (GWAS) n = 3468 [12] ; and 2013 Samoa STEPS (n = 1725) [6] . Estimates weighted to the most recent previous census to improve representativeness.
Sex-specific estimates adjusted for Division of residence and age. National estimates adjusted for Division of residence, sex and age. Diabetes = fasting plasma glucose ≥ 7.0 mmol/l and/or on medication. Mean fasting plasma glucose includes those on Type 2 diabetes mellitus medication.
Cut-off points for obesity: standard, BMI (Fig. 2 ). Based on current period trends, Type 2 diabetes mellitus prevalence projected to 2020 is estimated as 26% in men (95% PI, 14-39%) and women (95% PI, 15-38%).
Obesity
From meta-regression estimates, obesity prevalence (using BMI ≥ 30 kg/m 2 ) increased from 27.7% in 1978 to 53.1% in 2013 (3.6% per 5 years, P < 0.0001) in men, and from 44.4% in 1978 to 76.7% in 2013 (4.5% per 5 years, P < 0.0001) in women ( Table 1 , Fig. 1 ). Using BMI > 32 kg/m 2 , obesity prevalence increased from 24.7% in 1978 to 41.2% in 2013 in men (2.8% per 5 years, P = 0.07), and from 30.0% in 1978 to 65.1% in 2013 in women (4.8% per 5 years, P < 0.0001). Empirical estimates from the surveys are presented in Table 2 . Increases in obesity prevalence were highest in the youngest age group: 25-34 years at 4.6% per 5 years compared with 35-44 years at 4.3% per 5 years, 55-64 years at 4.2% per 5 years and 45-54 years at 4.2% per 5 years (Fig. 2) . Period projection of obesity prevalence in 2020 is 59% (95% PI, 45-73%) in men and 81% (95% PI, 71-91%) in women using standard cut-off points; or 47% (95% PI, 23-72%) in men and 71% (95% PI, 61-82%) in women using ethnicspecific cut-off points.
Sensitivity analyses
When the 1991 and 1995 SACRF surveys were excluded from meta-regression, there were small differences in the projections of Type 2 diabetes mellitus or obesity (BMI ≥ 30 kg/m 2 ) in 2020 (Fig. 1) . Projected 2020 Type 2 diabetes mellitus prevalences, based on meta-regression of six surveys, are 27% (men) and 26% (women). Projected 2020 obesity prevalences are 60% in men and 80% in women.
Effects of changes in age adjusted BMI on Type 2 diabetes mellitus period trends
After adjusting for age and BMI, the Type 2 diabetes mellitus RR in men (compared with 1978) was 2.2 [95% confidence interval (CI), 1.6 to 3.2, P < 0.0001), a decrease of 31% between the age-and age-and BMI-adjusted RR. In women, after adjusting for age and BMI, Type 2 diabetes mellitus RR was 2.1 (95% CI, 1.6 to 2.8, P < 0.0001), a decrease of 16% compared with age-only adjustment.
Discussion
Type 2 diabetes mellitus and obesity in Samoa increased in both sexes and across all age groups between 1978 and 2013. The prevalence of Type 2 diabetes mellitus is similar between sexes, but obesity is more prevalent in women than men. Based on current trends using meta-regression, we predict that more than one in four Samoan adults will have Type 2 diabetes mellitus in 2020 based on period trends. The increase in Type 2 diabetes mellitus is partially influenced by the rise in obesity. Similar results are seen in other Pacific Island countries where increases in mean BMI in Fiji Melanesians explained 27% (men) and 25% (women) of increases in Type 2 diabetes mellitus prevalence , after age adjustment [22] . In Tonga, BMI increases explained 76% (men) and 73% (women) of Type 2 diabetes mellitus prevalence increases over 1973-2012 [23] . BMI increases in Samoa, Fiji [22] and Tonga [23] have been attributed to changes in way of life, including a shift away from farming and fishing towards more sedentary occupations; and increased consumption of energy-dense imported foods [24] . The increase in Type 2 diabetes mellitus prevalence may be influenced by birth cohort effects, observed in the USA [25] . Over the period 1988-2010, US Type 2 diabetes mellitus prevalence rose with each successive birth cohort in conjunction with increases in population obesity. Obesity rates in Samoa are projected to continue increasing in the near future, and birth cohort influences may occur in this population, but these would need to be carefully separated from period effects in further analyses.
It is expected that Type 2 diabetes mellitus prevalence would be variable from multiple surveys in Samoa. All studies were included that met stated criteria -considered a desirable approach in meta-analyses [26] . Inclusion criteria were: measured blood glucose and BMI, and that the data could be adjusted to be nationally representative. Measurement bias was minimized by estimating known Type 2 diabetes mellitus when absent, converting blood or serum glucose concentrations to plasma equivalents, and using correct cut-offs for Type 2 diabetes mellitus. Selection bias was minimized by weighting samples to the closest previous census by age group and division of residence for each sex.
The use of meta-analysis to produce trends in Type 2 diabetes mellitus prevalence by meta-regression is preferable to selecting point estimates from empirical surveys because it smooths variations from unmeasured and unadjusted biases and confounding, augments participant numbers for analysis (greater statistical significance), weights studies by their sample size (SE), combines statistically heterogeneous studies through random effects analysis, and increases generalizability by including multiple studies from different periods and sites. A sensitivity analysis comparing meta-regression of all surveys, with that excluding the two surveys in which known cases of Type 2 diabetes mellitus were estimated (SACRF 1991 (SACRF , 1995 , revealed minimal changes in slope. Period projections of Type 2 diabetes mellitus and obesity prevalences to 2020 based on meta-regression (following logit transformation) are appropriate for short-term forecasting (2014-2020). Type 2 diabetes mellitus prevalence is expected to plateau at some time in the future.
The differences in Type 2 diabetes mellitus estimates between the two surveys in 1991 are likely to be a consequence of the selection effects from variations in modernization, development and urbanization within officially designated urban and rural areas based on large administrative Divisions. In the 1991 SACRF survey, the proportion of participants by Division was similar to the 1991 census: 21% Apia, 25% North West Upolu, 26% Rest of Upolu and 28% Savai'i [27] . However, the villages selected were the least developed, even within rural areas (personal communication, STM, 2014). The 1991 NCDRF survey did not recruit participants from North West Upolu Division, leading to a higher proportion from Apia (29%) [8, 9] , consistent with the purpose of the survey, which was to compare NCD risk factors between urban and rural populations. After adjusting for differences in sampling across Divisions, Type 2 diabetes mellitus prevalence remains higher in the 1991 NCDRF than the 1991 SACRF survey. This may partly be a consequence of selection of Tuasivi as the survey site in the rural Division of Savai'i in the 1978 and 1991 NCDRF surveys, which, as the ferry port and government centre, is less rural than the rest of island which was sampled in the 1991-1995 SACRF surveys.
The published 2002 STEPS Type 2 diabetes mellitus prevalence, weighted to the previous census, was 21 .5% [5] and in the present study was 20.7%. In the 2010 GWAS, published age-standardized Type 2 diabetes mellitus prevalence was 12.4% for men and 11.8% for women [12] , similar to our findings of 13.0% (men) and 14.0% (women).
The 2013 STEPS Type 2 diabetes mellitus is reported as 45.8% (age, sex and Division weighted to the 2011 census) [6] , This prevalence (twice that of the 2002 STEPS) was likely calculated from a whole-blood glucose cut-off point of 6.1 mmol/l (as used in 2002). We reproduced a similar Type 2 diabetes mellitus prevalence (49.7%) from the 2013 STEPS unit record data using this cut-off point (age, sex and Division adjusted to the 2011 census). The 2013 STEPS survey used a Roche Accutrend â plus glucose meter that produces readings in plasma equivalents [20] , and when using the appropriate plasma cut-off point of ≥ 7.0 mmol/l, yields a Type 2 diabetes mellitus prevalence of 24.3% -similar to 2002 STEPS (Appendix S3). The 2013 IDF Diabetes Atlas estimated Type 2 diabetes mellitus in Samoa, from modelled projections, as 7.7% [28] , significantly lower than our estimates of 19.5% from empirical surveys. The GBD reported that obesity prevalence in Samoan adults > 20 years increased from 37% to 46% in men and from 62% to 69% in women over 1980-2013 [29] compared with our estimates of 23.5% to 53.1% in men and 43.7% to 73.4% in women (25-64 years, 1978-2013) . Differences likely stem from the Diabetes Atlas and GBD analysis each using a single survey (1991 NCDRF for Type 2 diabetes mellitus; 2002 Samoa STEPS for obesity), compared with this study in which eight surveys are included. The Diabetes Atlas and the GBD also used extensive projection, whereas in this study interpolation is employed and extrapolation is limited and based on several surveys.
This study is the first to assess Type 2 diabetes mellitus and obesity prevalence trends using multiple cross-sectional health surveys in Samoa, adjusted to minimize differences in selection, measurement and case definition. Type 2 diabetes mellitus and other obesity-related conditions will continue to increase due to the large proportion of obese people, especially in women and the young. Continued aging would further increase Type 2 diabetes mellitus prevalence.
